D5pharma Inc.

Other

Clinique La Prairie Franchising S.a.

Reginald Gorczynski

Jean Gariépy

Aaron Prodeus

Jean-Pierre Mach

Christian Alexander

Ulrich Zahringer

Petra Hofmann

Artur Ulmer

Antonio Verdini

Artur J Ulmer

Ulrich Vor Dem Esche

Wolfgang Bessler

Alfred Hartman

Silke Muller

Thierry Walli

Alexander Westphal, Legal Representative

Josette Westphal, Legal Representative

Otto Westphal

Ulrich Zaehringer

Thierry Waelli

Alfred Hartmann

Silke Mueller

Disclosed are short DNA aptamers that selectively recognize CD200R1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, CD200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, asthma, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorder such as systemic lupus erythematosus, Parkinson's Disease, or multiple sclerosis.

DNA aptamers specific to CD2000R1 and their therapeutic uses

Disclosed are short DNA aptamers that selectively recognize CD200R1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, CD200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorders such as systemic lupus erythematosus, Parkinson's Disease, or multiple sclerosis.

DNA aptamers specific to CD200R1 and their therapeutic uses

The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the &#x3b3;-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition. The composition of the invention finds a variety of applications which have in common the stimulation of the immune system and the reversion in polarization of cytokines and chemokines from a Th2-directed response to a Th1-type response. The proposed applications would therefore include the treatment of allergic conditions, malignancies, chronic infections, autoimmune phenomena and age-related imbalances.

Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components

Growing community of inventors

Toronto, Canada

Reginald Gorczynski